We focus on FDA-approved GLP-1 care pathways.
Why is my GLP-1 expensive even with insurance?
This is a payment modifier: it applies inside whichever plan you're on, after coverage is confirmed but before the final price is set.
Having insurance doesn’t automatically mean an affordable price, and you’re not imagining it if it feels that way. A national KFF poll of U.S. adults found that 56% of people taking a GLP-1 describe it as difficult to afford, and 27% had insurance and still paid the full cost themselves.
A few reasons this happens even with coverage:
Your plan covers the drug, but at a high cost-sharing tier. Formularies group drugs into tiers, and GLP-1s are often placed on a specialty or non-preferred tier with coinsurance instead of a flat copay. Check your plan’s specific tier before assuming a price — see our formulary-check guide for how.
Prior authorization wasn’t approved, or hasn’t gone through yet. Even a plan that covers the drug can deny it as not-yet-medically-necessary until specific documentation is submitted, and this step has gotten far more common recently. Among Medicare Part D plans covering semaglutide and tirzepatide, prior-authorization requirements stayed under 25% until late 2023, then rose to roughly 83% by the third quarter of 2024. Our prior-authorization denial guide covers the most common reasons and what to do next.
The drug is billed for weight management instead of diabetes, or vice versa. Many plans cover the exact same medication differently depending on which diagnosis code it’s billed under.
If none of the above resolves it, manufacturer savings cards (commercial insurance only) and the Medicare GLP-1 Bridge are the two most common ways to bring down an insured-but-still-expensive price — see our copay assistance guide for the specifics.